Bill, K. L. J., Seligson, N. D., Hays, J. L., Awasthi, A., Demoret, B., Stets, C. W., … Chen, J. L. (2019). Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. The Oncologist, 24(7), 989–996. https://doi.org/10.1634/theoncologist.2019-0047

Bill, Kate Lynn J., Nathan D. Seligson, John L. Hays, Achal Awasthi, Bryce Demoret, Colin W. Stets, Megan C. Duggan, et al. “Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma.” The Oncologist 24, no. 7 (July 1, 2019): 989–96. https://doi.org/10.1634/theoncologist.2019-0047.

Bill KLJ, Seligson ND, Hays JL, Awasthi A, Demoret B, Stets CW, et al. Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. The Oncologist. 2019 Jul 1;24(7):989–96.

Bill, Kate Lynn J., et al. “Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma.” The Oncologist, vol. 24, no. 7, Oxford University Press (OUP), July 2019, pp. 989–96. Crossref, doi:10.1634/theoncologist.2019-0047.

Bill KLJ, Seligson ND, Hays JL, Awasthi A, Demoret B, Stets CW, Duggan MC, Bupathi M, Brock GN, Millis SZ, Shakya R, Timmers CD, Wakely PE, Pollock RE, Chen JL. Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. The Oncologist. Oxford University Press (OUP); 2019 Jul 1;24(7):989–996.